crossing96/oncoscreening huggingface dataset:
Transcription factor SPI1 exacerbates the malignant progression of esophageal squamous cell carcinoma byactivating LAMA3 expression.	Esophageal squamous cell carcinoma (ESCC) is the most common subtype of esophageal cancer (ESCA). ESCC is one of the malignancies with high incidence and mortality rates. Studies have found that laminin subunit alpha 3 (LAMA3) functions as an oncogene in a variety of cancers. SPI1 is highly expressed in ESCC, but whether LAMA3 and SPI1 regulate the development of ESCC is still unclear. In this study, bioinformatics analysis tools were used to predict the expression of LAMA3 and SPI1 in ESCA. Subsequently, the levels of mRNA and protein were respectively detected by RT-qPCR and WB. Then, the cell biological behaviors were measured by CCK-8, colony formation, EdU, and tube formation assays. To investigate the in vivo effects of LAMA3 knockdown on ESCC, a xenograft tumor model was established, followed by IHC analysis. Additionally, glucose consumption, lactate production, ROS, and Fe2+ levels were determined by the corresponding kits. Besides, the interaction of LAMA3 and SPI1 was examined by ChIP and dual luciferase reporter assays. LAMA3 was highly expressed in ESCC and silencing it could curb the viability and proliferation of ESCC cells, tumor growth in vivo, tube formation of HUVECs, and induce oxidative stress and ferroptosis of ESCC cells. SPI1 was highly expressed in ESCC and could bind to the promoter of LAMA3 to jointly regulate the progression of ESCC. This study elucidated that SPI1 aggravated ESCC by binding to the promoter of LAMA3, thereby stimulating the growth and proliferation of ESCC cells and suppressing oxidative stress and ferroptosis.	esophagus
CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients.	Claudin 18 isoform 2 (CLDN18.2) has emerged as a novel therapeutical target for HER2-negative, locally advanced, or metastatic gastroesophageal adenocarcinoma. However, reported prevalence rates vary widely (24-47%), underscoring the need for accurate population-specific data. This study investigates the CLDN18.2 prevalence in Spanish patients with gastroesophageal adenocarcinoma and explores its correlation with other biomarkers and clinicopathological factors. We retrospectively analyzed endoscopic biopsy samples from gastroesophageal adenocarcinoma patients across three Spanish institutions. CLDN18.2 expression was evaluated by immunohistochemistry using the Ventana CLDN18 (43-14A) assay and PS2+ scoring, with cases showing membranous 2+ or 3+ staining in ≥ 75% of tumor cells classified as positive. Clinicopathological and biomarker data were retrieved from medical records. CLDN18.2 was positive in 33% (89/270) of cases. Although histological type was not correlated with CLDN18.2 status, cases with poorly cohesive morphology exhibited heterogeneous staining, with a predominance of moderately and strongly stained cells. A weak to moderate inverse correlation was identified between signet ring cell content and CLDN18.2 staining (r = -0.29, p = 0.028). No significant differences were observed in clinical outcome. However, among patients with advanced-stage disease, CLDN18.2-positive intestinal tumors were associated with worse progression-free survival (HR 2.58, 95% CI 1.18-5.63; p = 0.029). These findings confirm a 33% prevalence of CLDN18.2 expression in the Spanish population, aligning with reports from other Western European cohorts. The significant heterogeneity in poorly cohesive cases and an inverse correlation with signet ring cell content pose diagnostic challenges for pathologists. Moreover, the association between CLDN18.2 positivity and worse progression-free survival in intestinal adenocarcinoma supports a potential role in tumor progression and metastasis, warranting further research.	esophagus
Global status and attributable risk factors of esophageal, stomach, colorectal cancers in adolescents and young adults: global burden of disease 2021 study analysis.	BACKGROUND AND AIMS: Digestive tract cancers, encompassing esophageal, stomach, colorectal cancers, account for about 20% of all cancer cases worldwide. This study seeks to examine the global epidemiological trends of these cancers in adolescents and young adults (AYA) from 1990 to 2021, as well as the related risk factors, to offer valuable insights for the formulation of health policies and the efficient distribution of public health resources. METHODS: Data from the Global Burden of Disease 2021 (GBD 2021) were utilized to conduct a comprehensive assessment of the global incidence, death, and disability-adjusted life years (DALYs) of digestive tract cancers within the AYA population. The correlation between cancer burden and socioeconomic development was examined by Socio-Demographic Index (SDI) regions. Use comparative risk assessment from GBD to evaluate risk factors for cancer deaths and DALYs. Assess incidence trends with BAPC model. RESULTS: The global burden of digestive tract cancer increased at different rates from 1990 to 2021. In 2021, colorectal cancer in AYA accounted for 70,201 incidences, 26,222 deaths, and 1,538,837 DALYs worldwide. In contrast, esophageal and stomach cancer had lower burdens in 8,164 and 42,039 incidences, respectively. While the incidence and death rates of esophageal and stomach cancers have declined, colorectal cancer have shown a significant increase in AYA. The age-standardized incidence rate (ASIR) of colorectal cancer correlates positively with SDI. In AYA, level 2 risk factors for colorectal cancer include alcohol use, dietary risks, high body mass index, high fasting plasma glucose, low physical activity, and tobacco. For esophageal cancer, the risk factors are alcohol use, dietary risks, and tobacco, and for stomach are dietary risks and tobacco. By 2040, the ASIR of the three digestive tract cancers in AYA will all decrease according to the BAPC model prediction. CONCLUSION: The study of digestive tract cancers in AYA serves to identify risk factors within the realm of public health, facilitate the rational allocation of medical resources. Moreover, it can attend to the physical and mental health requirements of AYA individuals and enhance the cognitive framework regarding cancer.	esophagus
Gastroduodenal Artery-Preserving Pancreatoduodenectomy after Esophagectomy with Gastric Conduit Reconstruction.	Pancreatoduodenectomy (PD) after esophagectomy with gastric conduit reconstruction is technically challenging. Preserving the blood supply of the gastric conduit is crucial in performing PD after esophagectomy. We report the case of a 66-year-old man who underwent gastroduodenal artery-preserving PD after esophagectomy with gastric conduit reconstruction for intraductal papillary mucinous neoplasm. The patient developed pseudoaneurysm rupture postoperatively, but was successfully treated with interventional radiology. Precise assessment is important in developing a surgical strategy depending on the patient's specific anatomy and tumor characteristics. Moreover, special attention should be paid to avoid accidental injuries of the gastric conduit and gastric vessels during surgery.	esophagus
Lipophilic integrated bioorthogonal self-catalyzed nitric oxide donor-platinum(IV) prodrugs for enhanced antitumor efficacy against esophageal cancer.	Esophageal cancer (EC) represents a globally prevalent malignancy with limited validated therapeutic targets, for which the cisplatin (CDDP)/5-fluorouracil (5-FU) combination remains the standard chemotherapy backbone. Nitric oxide (NO) and platinum(IV) complexes have attracted significant research interest in antitumor therapy. Previously designed integrated prodrugs suffered from poor cellular uptake. Herein, we reported the design, synthesis, and biological evaluation of a series of novel lipophilic integrated bioorthogonal self-catalyzed NO donor/Pt(IV) prodrugs, in which cytoplasmic reductants catalyze the release of Pt(Ⅱ) and NO to produce synergistic antitumor effects in cancer cells. In vitro biological studies revealed that 10k exhibited 1.3- to 4.4-fold lower IC(50) values than CDDP against esophageal cancer cell lines, correlating with significantly enhanced lipophilicity. The lipophilic modification at the axial position of complex 10k significantly enhanced cellular Pt accumulation and DNA platination in KYSE-520 cells by 10.4- and 4.7-fold, respectively, compared to CDDP. The preferred complex 10k demonstrated favorable stability and pharmacokinetic properties. Compared with CDDP, 10k exhibited potent in vivo anti-esophageal cancer effects (71.1% tumor growth inhibition (TGI) against the KYSE-520 xenograft model) as well as inhibited lung metastasis, without significant systemic toxicity. Overall, the integrated prodrug 10k represents a promising candidate for EC treatment and deserves further in-depth studies.	esophagus
Preoperative Diagnostic Value of Spectral CT for Predicting Perineural Invasion in Esophageal Cancer.	PURPOSE: To assess the diagnostic value of preoperative spectral CT quantitative parameters in predicting perineural invasion (PNI) in esophageal squamous cell carcinoma (ESCC), which is a critical prognostic factor associated with increased recurrence and poor survival. Preoperative identification of PNI can guide individualized treatment strategies. METHODS: A retrospective analysis was conducted on 78 patients with EC who underwent preoperative spectral CT. Patients were classified into PNI-positive and -negative groups on the basis of histopathological findings. Spectral CT parameters, including conventional single-energy CT value (Sect), virtual monochromatic images, effective atomic number (Zeff), and iodine concentration (IC), were compared between groups. Statistical analyses were performed through t, rank sum, and chi-squared tests. A diagnostic nomogram was constructed by employing independent predictors and validated via receiver operating characteristic curve analysis with DeLong's test for the pairwise comparison of the area under the curve (AUC), ensuring the robust evaluation of discriminative performance. RESULTS: Significant differences in spectral CT parameters were observed between the PNI-positive and PNI-negative groups. Specifically, the PNI-positive group exhibited higher values of 40-70 keV, Zeff, and IC (all p < 0.05) than the PNI-negative group. Among parameters, 40 keV demonstrated the highest predictive accuracy for PNI, with an AUC of 0.943. Binary logistic regression identified CYF, Sect, and 40 keV as independent predictors of PNI status. A nomogram incorporating these variables achieved the optimal diagnostic performance with an AUC of 0.971. CONCLUSION: Preoperative spectral CT quantitative parameters, particularly 40 keV, Zeff, and IC, provide valuable insights for assessing PNI in ESCC. The integration of spectral CT parameters with clinical features can significantly improve the accuracy of PNI diagnosis.	esophagus
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.	BACKGROUND: In the ARMANI trial, switch maintenance with paclitaxel plus ramucirumab improved progression-free survival and overall survival versus continuation of oxaliplatin-based chemotherapy in patients with HER2-negative advanced gastric or gastroesophageal junction cancer. Here, we report the health-related quality of life (HRQOL) outcomes. METHODS: ARMANI was a multicenter, randomized, open-label phase 3 trial. Patients achieving disease control after 3 months of FOLFOX or CAPOX were randomized to paclitaxel plus ramucirumab (arm A) or continued FOLFOX/CAPOX (arm B). HRQOL was assessed using EORTC QLQ-C30, QLQ-OG25, and EQ-5D-5L at baseline and every 8 weeks until progressive disease (PD). Endpoints included mean changes from baseline, distribution of improved/stable/worsened global QOL and time to deterioration (TTD; ≥10-point worsening in global QOL). RESULTS: Among 280 randomized patients, 198 (70.7 %) completed QOL at baseline; 121 (43.2 %) had also the 8-week assessment. Arm A led to improved global QOL at week 8 versus arm B, with more patients reporting improvement (24.7 % versus 4.2 %; delta +20.5 %, 95 % confidence interval [CI] +9.1 % - +31.2 %, p = 0.009) and longer TTD (7.6 versus 3.8 months; HR 0.52, 95 % CI 0.33 - 0.82; p = 0.005). Arm A improved role functioning, nausea/vomiting, pain, appetite loss, and dysphagia, while hair loss was more frequent. The improvement was maintained at subsequent timepoints, though not statistically significant. At PD, no differences in symptoms and domains scores were found by treatment arm. EQ VAS scores were numerically higher in arm A at each timepoint except PD. CONCLUSION: In patients with advanced HER2-negative gastric or gastroesophageal junction cancer, paclitaxel plus ramucirumab switch maintenance showed significant benefit in HRQOL, reducing symptoms and delaying global QOL deterioration.	esophagus
The Relevance of Lymphadenectomy Extension to the Right Paratracheal Space in the Treatment of Esophagogastric Junction Adenocarcinoma: A Retrospective Bicentric Study.	The benefit of extensive lymphadenectomy including the right paratracheal station (RPTS) in the upper mediastinum for esophagogastric junction (EGJ) adenocarcinoma remains controversial. Upper mediastinal lymph node (LN) involvement has been associated with esophageal invasion length, representing a potential research area. This study aimed to assess the rate of RPTS LN involvement in EGJ adenocarcinoma and its correlation with esophageal invasion length, as well as potential impacts on survival and postoperative complications. Patients undergoing two- or three-field esophagectomy with lymphadenectomy extended to the RPTS between 2006 and 2023 were retrospectively included. Patient, tumor, operative, and postoperative data were collected. Among 321 esophagectomies, 147 met inclusion criteria. Median esophageal invasion length was 3 cm. No patients (0%) had LN metastasis in the RPTS, regardless of invasion length (>4 cm or ≤4 cm). Postoperative complications occurred in 41.5% of patients, most commonly weight loss > 10% (29.2%), pleural effusion (21.1%), and infectious pneumonitis (19.7%). Five-year overall and disease-free survival rates were 44% and 29%, respectively. Our findings suggest that extending lymphadenectomy to the right paratracheal space fails to detect lymph node invasion in patients with esophageal invasion greater than or less than 4 cm in patients with esophageal adenocarcinoma.	esophagus
RegGAN-based contrast-free CT enhances esophageal cancer assessment: multicenter validation of automated tumor segmentation and T-staging.	PURPOSE: This study aimed to develop a deep learning (DL) framework using registration-guided generative adversarial networks (RegGAN) to synthesize contrast-enhanced CT (Syn-CECT) from non-contrast CT (NCCT), enabling iodine-free esophageal cancer (EC) T-staging. METHODS: A retrospective multicenter analysis included 1,092 EC patients (2013-2024) divided into training (N = 313), internal (N = 117), and external test cohorts (N = 116 and N = 546). RegGAN synthesized Syn-CECT by integrating registration and adversarial training to address NCCT-CECT misalignment. Tumor segmentation used CSSNet with hierarchical feature fusion, while T-staging employed a dual-path DL model combining radiomic features (from NCCT/Syn-CECT) and Vision Transformer-derived deep features. Performance was validated via quantitative metrics (NMAE, PSNR, SSIM), Dice scores, AUC, and reader studies comparing six clinicians with/without model assistance. RESULTS: RegGAN achieved Syn-CECT quality comparable to real CECT (NMAE = 0.1903, SSIM = 0.7723; visual scores: p ≥ 0.12). CSSNet produced accurate tumor segmentation (Dice = 0.89, 95% HD = 2.27 in external tests). The DL staging model outperformed machine learning (AUC = 0.7893-0.8360 vs. ≤ 0.8323), surpassing early-career clinicians (AUC = 0.641-0.757) and matching experts (AUC = 0.840). Syn-CECT-assisted clinicians improved diagnostic accuracy (AUC increase: ~ 0.1, p < 0.01), with decision curve analysis confirming clinical utility at > 35% risk threshold. CONCLUSIONS: The RegGAN-based framework eliminates contrast agents while maintaining diagnostic accuracy for EC segmentation (Dice > 0.88) and T-staging (AUC > 0.78). It offers a safe, cost-effective alternative for patients with iodine allergies or renal impairment and enhances diagnostic consistency across clinician experience levels. This approach addresses limitations of invasive staging and repeated contrast exposure, demonstrating transformative potential for resource-limited settings.	esophagus
A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.	Esophageal adenocarcinoma (EAC) has seen a dramatic rise in incidence in developed countries over the past three decades. Early detection of its precursors-gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and high-grade dysplasia (HGD) is critical for cancer prevention. This study presents the development and validation of a novel liquid biopsy assay based on circulating microbial DNA (cmDNA) for the early detection of EAC and HGD. Using metagenomic sequencing, we identified significant differences in microbial diversity and composition between EAC and HGD patients, as well as between BE and GERD patients. A total of 46 microbial candidates in tissue and 419 in serum were upregulated in EAC & HGD, with 11 consistently elevated in both sample types. Following qRT-PCR validation and LASSO regression, a 6-marker cmDNA panel was selected. This signature was incorporated into a diagnostic model trained with the XGBoost algorithm, achieving an AUC of 0.93 in the training cohort (52 HGD & EAC cases vs. 54 BE & GERD controls). Importantly, the model demonstrated robust performance in an independent testing cohort (23 HGD & EAC cases vs. 22 BE & GERD controls), yielding AUCs of 0.91 for EAC and 0.88 for HGD. These findings highlight the diagnostic potential of cmDNA-based profiling and support its utility as a minimally invasive, accurate, and generalizable tool for early detection of esophageal adenocarcinoma.	esophagus
Hepatectomy for oligometastatic liver disease in oesophageal adenocarcinoma: The METHEOR study.	BACKGROUND: Oesophageal cancer is metastatic at diagnosis in 40 % of cases, with liver metastasis (LM) being the second most frequent site. In oligometastatic patients, the survival benefit of ablative therapy over chemotherapy remains unclear. This study aims to evaluate the impact of liver resection on overall and progression-free survival in patients with limited LM from Oesophageal Adenocarcinoma (OA) or Siewert I-II Oeso-Gastric Junction Adenocarcinoma (OGJA). METHODS: This retrospective, multicenter national study included patients treated between 2000 and 2015 in 17 centers. Eligible patients had OA or OGJA, WHO performance status ≤2, and ≤3 resectable, isolated LM. Patients were assigned to two groups: LM ablation with systemic chemotherapy (ablation group) or systemic chemotherapy alone (control group). Exclusion criteria included age >75, extrahepatic disease, non-operable patients, or those who cannot be included in a chemo(radio)therapy-based treatment strategy. RESULTS: Fifty-four patients were included: 31 in the ablation group (57 %) and 23 in the control group (43 %). Both groups were comparable in terms of demographic characteristics, OA, cTNM stage, LM number (p = 0.166) and size (p = 0.622), and timing of metastasis. Postoperative mortality at 90 days was 3.2 %, and severe complications (Clavien-Dindo ≥3) occurred in 12.9 %. Median follow-up was 72 months. Median overall survival and progression-free survival were significantly longer in the ablation group: 36.7 vs. 14.9 months, and 17.7 vs. 9.0 months respectively. LM ablation and pN + status were independently associated with OS. In the ablation group, pN + remained a significant prognostic factor. CONCLUSION: Liver resection for isolated LM in OA and OGJA improved overall and progression-free survival compared to chemotherapy alone. A curative-intent approach is feasible in selected patients.	esophagus
PIK75 effectively reverses PI3K‒AKT activation caused by palbociclib resistance and synergistically inhibits the progression of esophageal squamous cell carcinoma.	China is one of the countries with a high incidence of esophageal squamous cell carcinoma (ESCC). At present, the main treatment method for ESCC is surgery combined with chemotherapy and radiotherapy, and the efficacy of drug therapy is not ideal. Cyclin-dependent kinase inhibitors (CDKi) have shown amazing efficacy in treating some types of cancer, especially breast cancer, but their therapeutic effects on ESCC are limited. In the present study, we found that the CDK inhibitor palbociclib could successfully arrest cells in the G0/G1 phase but did not inhibit the proliferation of some types of ESCC cells. Further experiments revealed that activation of the PI3K‒AKT pathway was key for palbociclib resistance. Therefore, we investigated the potential of combining palbociclib with the novel PI3K inhibitor PIK75 to inhibit the growth of ESCC cell lines and xenograft tumors. The combined use of palbociclib and PIK75 synergistically inhibited the expression of the cell cycle proteins CCNE1, CDC6, and CDC25A, as well as the abnormal activation of PIK3CA and AKT phosphorylation. The combination of these two drugs synergistically inhibited tumor cell cycle progression and promoted apoptosis in vitro and in vivo, which provides a promising idea for the treatment of ESCC in the future.	esophagus
Management of MOG antibody-associated disease by pembrolizumab and radiation myelopathy in an elderly patient: A case report and literature review.	Immunotherapy and radiotherapy are important means for treating solid tumors. Both treatment methods can potentially cause neurologic injuries. Timely identification, diagnosis, and early treatment play a crucial role in the recovery from neurologic damage. This case report describes a 69-year-old woman with esophageal and oropharyngeal cancer who developed neurological complications after radiotherapy and immunotherapy. She experienced radiation-related motor impairment and symptoms returned after treatment with bevacizumab and corticosteroids. Later, she developed a rare demyelinating neuropathy, diagnosed as MOG antibody-associated disease (MOGAD), likely triggered by immune checkpoint inhibitors, which is a very rare adverse drug reaction. Her condition improved with cessation of immunotherapy and the administration of steroid pulse therapy. Despite treatment interruptions due to side effects, her survival period was favorable, suggesting that reduced-dose therapy in elderly patients may not diminish its antitumor effect. This case emphasizes the need for vigilance in recognizing rare complications and rational antitumor treatment intensity in geriatric oncology.	esophagus